



## Wayland Group Receives Receipt for Final Prospectus for Previously Announced Bought Deal Financing

**THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWswire SERVICES OR DISSEMINATION IN THE UNITED STATES.**

TORONTO, Oct. 25, 2018 -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) ("Wayland" or the "Company") announced today that it has received a receipt for a final prospectus (the "Prospectus") of the Company from the securities regulators in each of the provinces of Canada (other than Quebec) with respect to its previously announced \$50,000,000 bought deal offering of units of the Company (the "Offering").

The Offering is expected to close on October 31, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including approval of the Canadian Securities Exchange and applicable securities regulatory authorities. The Company intends to use the net proceeds from the Offering for expansion of its facility at 138, 8<sup>th</sup> Concession Road in Langton, Ontario and for working capital and general corporate purposes.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

Maricann Group Inc., through its subsidiaries, is operating under the Wayland Group name. For further details see the press release dated September 24, 2018.

### **About Wayland Group**

Wayland is a vertically integrated producer and distributor of marijuana for medical purposes. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.

### **Forward Looking Information**

*This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include those relating to the proposed Offering, the use of proceeds and the anticipated Closing Date thereof. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.*

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

For more information about Wayland, please visit our website at [www.waylandgroup.com](http://www.waylandgroup.com)

### **Contact Information:**

Investor Relations  
Graham Farrell  
VP, Communications  
[Graham.farrell@waylandgroup.com](mailto:Graham.farrell@waylandgroup.com)  
647-643-7665

**Media Inquiries:** [media@waylandgroup.com](mailto:media@waylandgroup.com)

Corporate Headquarters (Canada)  
Wayland Group Corp. (Toronto)  
845 Harrington Court, Unit 3  
Burlington Ontario L7N 3P3  
Canada  
289-288-6274

European Headquarters (Germany)  
Maricann GmbH  
Thierschstrasse 3, 80538 Munchen, Deutschland